TGFB1 and cancer: Our model fits a scenario where the C-ECM-down signature represents normal/normal-like fibroblasts, whereas the TGF-β-driven C-ECM-up signature identifies a poor prognosis CAF activation phenotype that is upregulated pan-cancer.